NCL joins 25+ advocacy organizations in opposing expansion of 340B drug pricing program in New York
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829
Washington, DC – Today, the National Consumers League (NCL) joined over 25 patient and provider advocacy organizations in voicing strong opposition to the proposed expansion of the 340B Drug Pricing Program under NY Senate Bill 1913. The groups, which represent a broad coalition of patients, healthcare providers, and consumer advocates, assert that the 340B program, originally designed to support vulnerable populations, has instead become a profit-driven mechanism benefiting large hospital systems and middlemen—without delivering on its promises to the low-income individuals it was meant to help.
“The 340B program was designed to help vulnerable patients, but it’s become a profit-driven system that benefits hospitals, not those in need,” said Samantha Sears, Health Policy Associate at NCL. “It’s time for policymakers to demand real accountability and transparency.”
Without these changes, 340B will continue to drive up costs while failing to serve those who need it most. Rather than expanding a flawed and dysfunctional system, the coalition is urging state legislators to take meaningful action to reform 340B. They are calling for:
- Greater transparency on how 340B savings are reinvested into patient care.
- Direct benefits to lower drug costs for uninsured patients.
- A focus on expanding the program in truly underserved areas.
The full letter is available here.
###
About the National Consumers League (NCL)
The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit nclnet.org.
